If everything goes according to plan they will not need to raise capital again. With $90 M in cash, they have enough cash until the end of 2019. But if Emricasan works as we think, there will be $657M to be cashed in probably even before Emricasan hits the market. So with $750M in cash there should be more than enough to take care of G&A and other compounds future development plans for the foreseeable (I doubt they would venture in expensive acquisitions, since, if any, these will be pre-clinical or early clinical compounds as already outlined by S Mento)
News 
Market Data 
Discover 
